What does serpatinib treat?

Selpercatinib (Selpercatinib) is an oral targeted anti-tumor drug with relatively broad and specific indications. The following are the main indications for serpatinib:

Non-small cell lung cancer (NSCLC):

Serpatinib has shown significant efficacy in adults with RET fusion-positive non-small cell lung cancer that has spread Clinical data shows that serpatinib can block the growth and spread of tumors, providing patients with new treatment options. In relevant clinical trials, such as the LIBRETTO-001 trial, serpatinib achieved a high objective response rate (ORR) in patients with non-small cell lung cancer, proving its effectiveness in this field.

Medullary thyroid cancer (MTC):

Selpatinib is also indicated for the treatment of advanced or metastatic medullary thyroid cancer, especially those withRET gene mutations. Serpatinib has shown good therapeutic effects in both adults and children aged 12 years and above. In clinical trials, the drug also achieved satisfactory response rates in patients with medullary thyroid cancer.

Thyroid cancer with RET gene fusion:

Serpatinib also has significant efficacy in adult and pediatric patients with advanced or metastatic thyroid cancer with RET gene fusions. Serpatinib offers new treatment opportunities for these patients, who often do not respond well to traditional treatments. Clinical trial data shows that the drug also has relatively high response rates in such patients.

It should be noted that when using serpatinib, patients must follow the doctor’s recommendations and prescriptions for correct usage and dosage. At the same time, you should pay close attention to adverse reactions and promptly report any abnormalities to your doctor.

References:

https://www.drugs.com/monograph/selpercatinib.html